Vor Biopharma plunges on steeply discounted $100 mln stock offering

Vor Biopharma

11/11/2025 11:40

** Vor Biopharma's VOR.O shares down 30.7% premarket to $13.02 after $100 mln follow-on priced at deep discount

    ** Autoimmune disease-focused biotech late Mon sold 10 mln shares at $10, 46.8% below stock's last close of $18.80

    ** Co intends to use net offering proceeds to advance clinical development for its drug, telitacicept, including initiation of a Phase 3 clinical trial, per the prospectus

** Boston-based VOR has ~6.3 mln shares outstanding; in Sept, co effected a 1-for-20 reverse stock split

** JP Morgan, Jefferies, Citigroup and TD Cowen are joint bookrunners for offering

** Through Mon close, shares had gained about 450% over the past six months, leaving them down ~15% YTD

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))